Investigational Drug Information for Retosiban
✉ Email this page to a colleague
What is the development status for investigational drug Retosiban?
Retosiban is an investigational drug.
There have been 8 clinical trials for Retosiban.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 16th 2015.
The most common disease conditions in clinical trials are Obstetric Labor, Premature, Premature Birth, and [disabled in preview]. The leading clinical trial sponsors are GlaxoSmithKline, PPD, and Tel-Aviv Sourasky Medical Center.
There are thirteen US patents protecting this investigational drug and one hundred and forty-three international patents.
Summary for Retosiban
| US Patents | 13 |
| International Patents | 143 |
| US Patent Applications | 39 |
| WIPO Patent Applications | 17 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 3 (2015-03-16) |
| Vendors | 30 |
Recent Clinical Trials for Retosiban
| Title | Sponsor | Phase |
|---|---|---|
| Tocolytic Therapy for Preterm Labor in Multiple Gestation | Tel-Aviv Sourasky Medical Center | Phase 3 |
| A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor | PPD | Phase 3 |
| A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor | GlaxoSmithKline | Phase 3 |
Clinical Trial Summary for Retosiban
Top disease conditions for Retosiban
Top clinical trial sponsors for Retosiban
US Patents for Retosiban
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Retosiban | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Retosiban | ⤷ Sign Up | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies | Ferring B.V. (Hoofddorp, NL) | ⤷ Sign Up |
| Retosiban | ⤷ Sign Up | Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof | Merck Serono S.A. (Coinsins, CH) | ⤷ Sign Up |
| Retosiban | ⤷ Sign Up | Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies | FERRING B.V. (Hoofddorp, NL) | ⤷ Sign Up |
| Retosiban | ⤷ Sign Up | Substituted diketopiperazines and their use as oxytocin antagonists | Glaxo Group Limited (Greenford, Middlesex, GB) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Retosiban
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Retosiban | Australia | AU2017261372 | 2036-05-05 | ⤷ Sign Up |
| Retosiban | Canada | CA3023278 | 2036-05-05 | ⤷ Sign Up |
| Retosiban | China | CN107847398 | 2036-05-05 | ⤷ Sign Up |
| Retosiban | European Patent Office | EP3452003 | 2036-05-05 | ⤷ Sign Up |
| Retosiban | European Patent Office | EP3981392 | 2036-05-05 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
